Home › Trial NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Trial IDNCT05131022
- StatusRecruiting
- PhasePhase 1
- Study typeInterventional
- SponsorNurix Therapeutics, Inc.
- Enrollment572
- Start date2022-04-13
- ConditionsChronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL) · Diffuse Large B Cell Lymphoma (DLBCL) · Follicular Lymphoma (FL) · Mantle Cell Lymphoma (MCL) · Marginal Zone Lymphoma (MZL)
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.